Araya-Kojima Tomoko, Yaeshima Tomoko Ishibashi Norio Shimamura Seiichi Hayasawa Hirotoshi. Inhibitory Effects of Bifidobacterium longum BB536 on Harmful Intestinal Bacteria. Bifidobacteria Microflora 1995;14(2):59-66.
Ballongue J, Grill J Baratte-Euloge P. Action sur la flore intestinale de laits fermentés au Bifidobacterium. Lait 1993;73:249-256.
Bennet, R., Nord, C. E., and Zetterstrom, R. Transient colonization of the gut of newborn infants by orally administered bifidobacteria and lactobacilli. Acta Paediatr. 1992;81(10):784-787. View abstract.
Chouraqui, J. P., Grathwohl, D., Labaune, J. M., Hascoet, J. M., de, Montgolfier, I, Leclaire, M., Giarre, M., and Steenhout, P. Assessment of the safety, tolerance, and protective effect against diarrhea of infant formulas containing mixtures of probiotics or probiotics and prebiotics in a randomized controlled trial. Am.J Clin.Nutr. 2008;87(5):1365-1373. View abstract.
Das RR.Singh M, Shafiq N. Probiotics in Treatment of Allergic Rhinitis. World Allergy Organization Journal 2010;3(9):239-244.
del Giudice, M. M. and Brunese, F. P. Probiotics, prebiotics, and allergy in children: what's new in the last year? J Clin.Gastroenterol. 2008;42 Suppl 3 Pt 2:S205-S208. View abstract.
Dimidi E, Zdanaviciene A, Christodoulides S, et al. Randomised clinical trial: Bifidobacterium lactis NCC2818 probiotic vs placebo, and impact on gut transit time, symptoms, and gut microbiology in chronic constipation. Aliment Pharmacol Ther. 2019;49(3):251-264. View abstract.
Firmansyah, A., Dwipoerwantoro, P. G., Kadim, M., Alatas, S., Conus, N., Lestarina, L., Bouisset, F., and Steenhout, P. Improved growth of toddlers fed a milk containing synbiotics. Asia Pac.J Clin.Nutr. 2011;20(1):69-76. View abstract.
Gianotti, L., Morelli, L., Galbiati, F., Rocchetti, S., Coppola, S., Beneduce, A., Gilardini, C., Zonenschain, D., Nespoli, A., and Braga, M. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol. 1-14-2010;16(2):167-175. View abstract.
Igarashi M, Iiyama Y Kato R Tomita M Asami N Ezawa I. Effect of Bifidobacterium longum and lactulose on the strength of bone in ovariectomized osteoporosis model rates. Bifidus 1994;7:139-147.
Iwabuchi N, Hiruta N Kanetada S Yaeshima T Iwatsuki K Yasui H. Effects of Intranasal Administration of Bifidobacterium longum BB536 on Mucosal Immune System in Respiratory Tract and Influenza Virus Infection in Mice. Milk Science 2009;38(3):129-133.
Iwabuchi, N., Takahashi, N., Xiao, J. Z., Miyaji, K., and Iwatsuki, K. In vitro Th1 cytokine-independent Th2 suppressive effects of bifidobacteria. Microbiol.Immunol. 2007;51(7):649-660. View abstract.
Iwabuchi, N., Takahashi, N., Xiao, J. Z., Yonezawa, S., Yaeshima, T., Iwatsuki, K., and Hachimura, S. Suppressive effects of Bifidobacterium longum on the production of Th2-attracting chemokines induced with T cell-antigen-presenting cell interactions. FEMS Immunol.Med.Microbiol. 2009;55(3):324-334. View abstract.
Iwabuchi, N., Xiao, J. Z., Yaeshima, T., and Iwatsuki, K. Oral administration of Bifidobacterium longum ameliorates influenza virus infection in mice. Biol.Pharm.Bull. 2011;34(8):1352-1355. View abstract.
Kageyama T, Nakano Y Tomoda T. Comparative Study on Oral Administration of Some Bifidobacterium Preparations. Medicine and Biology(Japan) 1987;115(2):65-68.
Kageyama T, Tomoda T Nakano Y. The Effect of Bifidobacterium Administration in Patients with Leukemia. Bifidobacteria Microflora. 1984;3(1):29-33.
Kondo, J., Xiao, J. Z., Shirahata, A., Baba, M., Abe, A., Ogawa, K., and Shimoda, T. Modulatory effects of Bifidobacterium longum BB536 on defecation in elderly patients receiving enteral feeding. World J Gastroenterol 4-14-2013;19(14):2162-2170. View abstract.
Namba, K., Hatano, M., Yaeshima, T., Takase, M., and Suzuki, K. Effects of Bifidobacterium longum BB536 administration on influenza infection, influenza vaccine antibody titer, and cell-mediated immunity in the elderly. Biosci.Biotechnol.Biochem. 2010;74(5):939-945. View abstract.
Odamaki, T., Sugahara, H., Yonezawa, S., Yaeshima, T., Iwatsuki, K., Tanabe, S., Tominaga, T., Togashi, H., Benno, Y., and Xiao, J. Z. Effect of the oral intake of yogurt containing Bifidobacterium longum BB536 on the cell numbers of enterotoxigenic Bacteroides fragilis in microbiota. Anaerobe. 2012;18(1):14-18. View abstract.
Odamaki, T., Xiao, J. Z., Iwabuchi, N., Sakamoto, M., Takahashi, N., Kondo, S., Iwatsuki, K., Kokubo, S., Togashi, H., Enomoto, T., and Benno, Y. Fluctuation of fecal microbiota in individuals with Japanese cedar pollinosis during the pollen season and influence of probiotic intake. J Investig.Allergol.Clin.Immunol. 2007;17(2):92-100. View abstract.
Odamaki, T., Xiao, J. Z., Iwabuchi, N., Sakamoto, M., Takahashi, N., Kondo, S., Miyaji, K., Iwatsuki, K., Togashi, H., Enomoto, T., and Benno, Y. Influence of Bifidobacterium longum BB536 intake on faecal microbiota in individuals with Japanese cedar pollinosis during the pollen season. J Med.Microbiol. 2007;56(Pt 10):1301-1308. View abstract.
Odamaki, T., Xiao, J. Z., Sakamoto, M., Kondo, S., Yaeshima, T., Iwatsuki, K., Togashi, H., Enomoto, T., and Benno, Y. Distribution of different species of the Bacteroides fragilis group in individuals with Japanese cedar pollinosis. Appl.Environ.Microbiol. 2008;74(21):6814-6817. View abstract.
Ogata T, Kingaku M Yaeshima T Teraguchi S Fukuwatari Y Ishibashi N Hayasawa H Fujisawa T Lino H. Effect of Bifidobacterium longum BB536 yogurt administration on the intestinal environment of healthy adults. Microb Ecol Health Dis 1999;11:41-46.
Ogata T, Nakamura T Anjitsu K Yaeshima T Takahashi S Fukuwatari Y Ishibashi N Hayasawa H Fujisawa T Iino H. Effect of Bifidobacterium longum BB536 administration on the intestinal environment, defecation frequency and fecal characteristics of human volunteers. Biosci Microflora 1997;16:53-58.
Orrhage, K., Sjostedt, S., and Nord, C. E. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. J Antimicrob.Chemother. 2000;46(4):603-612. View abstract.
Puccio, G., Cajozzo, C., Meli, F., Rochat, F., Grathwohl, D., and Steenhout, P. Clinical evaluation of a new starter formula for infants containing live Bifidobacterium longum BL999 and prebiotics. Nutrition 2007;23(1):1-8. View abstract.
Rouge, C., Piloquet, H., Butel, M. J., Berger, B., Rochat, F., Ferraris, L., Des, Robert C., Legrand, A., de la Cochetiere, M. F., N'Guyen, J. M., Vodovar, M., Voyer, M., Darmaun, D., and Roze, J. C. Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. Am.J Clin.Nutr. 2009;89(6):1828-1835. View abstract.
Seki M, Igarashi T Fukuda Y Simamura S Kaswashima T Ogasa K. The effect of Bifidobacterium cultured milk on the "regularity" among an aged group. Nutr Foodstuff 1978;31:379-387.
Soh, S. E., Aw, M., Gerez, I., Chong, Y. S., Rauff, M., Ng, Y. P., Wong, H. B., Pai, N., Lee, B. W., and Shek, L. P. Probiotic supplementation in the first 6 months of life in at risk Asian infants--effects on eczema and atopic sensitization at the age of 1 year. Clin.Exp.Allergy 2009;39(4):571-578. View abstract.
Takeda, Y., Nakase, H., Namba, K., Inoue, S., Ueno, S., Uza, N., and Chiba, T. Upregulation of T-bet and tight junction molecules by Bifidobactrium longum improves colonic inflammation of ulcerative colitis. Inflamm.Bowel.Dis. 2009;15(11):1617-1618. View abstract.
Tang, M. L., Lahtinen, S. J., and Boyle, R. J. Probiotics and prebiotics: clinical effects in allergic disease. Curr.Opin.Pediatr. 2010;22(5):626-634. View abstract.
Tomoda T, Nakano Y Kageyama T. Intestinal Candida Overgrowth and Candida Infection in Patients with Leukemia: Effect of Bifidobacterium Administration. Bifidobacteria Microflora 1988;7(2):71-74.
Tomoda T, Nakano Y Kageyama T. Variation in Small Groups of Constant Intestinal Flora during Administration of Anticancer or Immunosuppressive Drugs. Medicine and Biology(Japan) 1981;103(1):45-49.
Xiao J, Kondol S Odamaki T Miyaji K Yaeshima T Iwatsuki K Togashi H Benno Y. Effect of yogurt containing Bifidobacterium longum BB 536 on the defecation frequency and fecal characteristics of healthy adults: A double-blind cross over study. Japanese Journal of Lactic Acid Bacteria 2007;18(1):31-36.
Xiao, J. Z., Kondo, S., Takahashi, N., Odamaki, T., Iwabuchi, N., Miyaji, K., Iwatsuki, K., and Enomoto, T. Changes in plasma TARC levels during Japanese cedar pollen season and relationships with symptom development. Int.Arch.Allergy Immunol. 2007;144(2):123-127. View abstract.
Xiao, J. Z., Kondo, S., Yanagisawa, N., Miyaji, K., Enomoto, K., Sakoda, T., Iwatsuki, K., and Enomoto, T. Clinical efficacy of probiotic Bifidobacterium longum for the treatment of symptoms of Japanese cedar pollen allergy in subjects evaluated in an environmental exposure unit. Allergol.Int. 2007;56(1):67-75. View abstract.
Xiao, J. Z., Kondo, S., Yanagisawa, N., Takahashi, N., Odamaki, T., Iwabuchi, N., Iwatsuki, K., Kokubo, S., Togashi, H., Enomoto, K., and Enomoto, T. Effect of probiotic Bifidobacterium longum BB536 [corrected] in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season. A randomized double-blind, placebo-controlled trial. J Investig.Allergol.Clin.Immunol. 2006;16(2):86-93. View abstract.
Xiao, J. Z., Kondo, S., Yanagisawa, N., Takahashi, N., Odamaki, T., Iwabuchi, N., Miyaji, K., Iwatsuki, K., Togashi, H., Enomoto, K., and Enomoto, T. Probiotics in the treatment of Japanese cedar pollinosis: a double-blind placebo-controlled trial. Clin.Exp.Allergy 2006;36(11):1425-1435. View abstract.
Yaeshima T, Takahashi S Matsumoto N Ishibashi N Hayasawa H Lino H. Effect of yogurt containing Bifidobacterium longum BB536 on the intestinal environment, fecal characteristics and defecation frequency: A comparison with standard yogurt. Biosci Microflora 1997;16:73-77.
Yaeshima T, Takahashi S Ogura A Konno T Iwatsuki K Ishibashi N Hayasawa H. Effect of Non-fermented Milk Containing Bifidobacterium longum BB536 on the Defecation Frequency and Fecal Characteristics in Healthy Adults. Journal of Nutrition Food 2001;4(2):1-6.
Yaeshima T, Takahashi S Ota S Nakagawa K Ishibashi N Hiramatsu A Ohashi T Hayasawa H Iino H. Effect of sweet yogurt containing Bifidobacterium longum BB536 on defecation frequency and fecal characteristics of healthy adults: A comparison with sweet standard yogurt. Kenko Eiyo Shokuhin Kenkyu 1998;1(3/4):29-34.
Yamazaki, S., Machii, K., Tsuyuki, S., Momose, H., Kawashima, T., and Ueda, K. Immunological responses to monoassociated Bifidobacterium longum and their relation to prevention of bacterial invasion. Immunology 1985;56(1):43-50. View abstract.
Al Faleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2014;(4):CD005496. View abstract.
Alanzi A, Honkala S, Honkala E, Varghese A, Tolvanen M, Söderling E. Effect of Lactobacillus rhamnosus and Bifidobacterium lactis on gingival health, dental plaque, and periodontopathogens in adolescents: a randomised placebo-controlled clinical trial. Benef Microbes. 2018;9(4):593-602. View abstract.
AlFaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.: CD005496. DOI: 10.1002/14651858.CD005496.pub3. View abstract.
Allen SJ, Jordan S, Storey M, Thornton CA, Gravenor MB, Garaiova I, Plummer SF, Wang D, Morgan G. Probiotics in the prevention of eczema: a randomised controlled trial. Arch Dis Child 2014;99(11):1014-9. View abstract.
Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, Dhar A, Brown H, Foden A, Gravenor MB, Mack D. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013 Oct 12;382(9900):1249-57. View abstract.
Amat-Bou M, Garcia-Ribera S, Climent E, et al. Effects of Bifidobacterium animalis Subsp. lactis (BPL1) supplementation in children and adolescents with prader-willi syndrome: A randomized crossover trial. Nutrients. 2020;12(10):3123. View abstract.
Arunachalam K, Gill HS, Chandra RK. Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019). Eur J Clin Nutr 2000;54:263-7. View abstract.
Bastürk A, Artan R, Yilmaz A. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial. Turk J Gastroenterol 2016;27(5):439-43. View abstract.
Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 2013;48(10):1127-35. View abstract.
Bernini LJ, Simão AN, Alfieri DF, et al. Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome. Nutrition. 2016;32(6):716-9. View abstract.
Bertelli C, Pillonel T, Torregrossa A, et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis 2015;60(6):924-7. View abstract.
Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539-46. View abstract.
Blaabjerg S, Artzi DM, Aabenhus R. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2017;6(4). View abstract.
Butler CC, Lau M, Gillespie D, et al. Effect of probiotic use on antibiotic administration among care home residents: A randomized clinical trial. JAMA. 2020;324(1):47-56. View abstract.
Callaway LK, McIntyre HD, Barrett HL, et al. Probiotics for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Women: Findings From the SPRING Double-Blind Randomized Controlled Trial. Diabetes Care. 2019;42(3):364-371. View abstract.
Abbas, D. K., Thrane, P., and Othman, S. J. Effectiveness of Veadent as a plaque-inhibiting mouthwash. Scand J Dent.Res 1985;93(6):494-497. View abstract.
Affleck, A. G. and Varma, S. A case of do-it-yourself Mohs' surgery using bloodroot obtained from the internet. Br.J Dermatol 2007;157(5):1078-1079. View abstract.
Allen, C. L., Loudon, J., and Mascarenhas, A. K. Sanguinaria-related leukoplakia: epidemiologic and clinicopathologic features of a recently described entity. Gen.Dent. 2001;49(6):608-614. View abstract.
Babay, N. and Al Jasser, N. Subgingival irrigation effects of chlorhexidine or sanguinarine on gingivitis in orthodontic patients. J Clin Pediatr Dent. 1996;20(3):225-228. View abstract.
Babu, J. P., Waring, M. B., Lyne, S. M., and Dabbous, M. K. Antiplaque activity of a sanguinaria-containing oral rinse: an in vitro study. Compend.Contin.Educ.Dent. 1986;Suppl 7:S209-S211. View abstract.
Colau, J. C., Vincent, S., Marijnen, P., and Allaert, F. A. Efficacy of a non-hormonal treatment, BRN-01, on menopausal hot flashes: a multicenter, randomized, double-blind, placebo-controlled trial. Drugs R.D 9-1-2012;12(3):107-119. View abstract.
Cullinan, M. P., Powell, R. N., Faddy, M. J., and Seymour, G. J. Efficacy of a dentifrice and oral rinse containing sanguinaria extract in conjunction with initial periodontal therapy. Aust.Dent.J. 1997;42(1):47-51. View abstract.
Etemadzadeh, H. and Ainamo, J. Lacking anti-plaque efficacy of 2 sanguinarine mouth rinses. J Clin Periodontol. 1987;14(3):176-180. View abstract.
Eversole, L. R., Eversole, G. M., and Kopcik, J. Sanguinaria-associated oral leukoplakia: comparison with other benign and dysplastic leukoplakic lesions. Oral Surg.Oral Med.Oral Pathol.Oral Radiol.Endod. 2000;89(4):455-464. View abstract.
Frankos, V. H., Brusick, D. J., Johnson, E. M., Maibach, H. I., Munro, I., Squire, R. A., and Weil, C. S. Safety of Sanguinaria extract as used in commercial toothpaste and oral rinse products. J.Can.Dent.Assoc. 1990;56(7 Suppl):41-47. View abstract.
Godowski, K. C. Antimicrobial action of sanguinarine. J Clin Dent. 1989;1(4):96-101. View abstract.
Godowski, K. C., Wolff, E. D., Thompson, D. M., Housley, C. J., Polson, A. M., Dunn, R. L., Duke, S. P., Stoller, N. H., and Southard, G. L. Whole mouth microbiota effects following subgingival delivery of sanguinarium. J Periodontol. 1995;66(10):870-877. View abstract.
Greenfield, W. and Cuchel, S. J. The use of an oral rinse and dentifrice as a system for reducing dental plaque. Compend Cont Educ Dent 1984;(Supp 5):S82-S86.
Grossman, E., Meckel, A. H., Isaacs, R. L., Ferretti, G. A., Sturzenberger, O. P., Bollmer, B. W., Moore, D. J., Lijana, R. C., and Manhart, M. D. A clinical comparison of antibacterial mouthrinses: effects of chlorhexidine, phenolics, and sanguinarine on dental plaque and gingivitis. J Periodontol. 1989;60(8):435-440. View abstract.
Hannah, J. J., Johnson, J. D., and Kuftinec, M. M. Long-term clinical evaluation of toothpaste and oral rinse containing sanguinaria extract in controlling plaque, gingival inflammation, and sulcular bleeding during orthodontic treatment. Am.J.Orthod.Dentofacial Orthop. 1989;96(3):199-207. View abstract.
Harper, D. S., Mueller, L. J., Fine, J. B., Gordon, J., and Laster, L. L. Clinical efficacy of a dentifrice and oral rinse containing sanguinaria extract and zinc chloride during 6 months of use. J.Periodontol. 1990;61(6):352-358. View abstract.
Harper, D. S., Mueller, L. J., Fine, J. B., Gordon, J., and Laster, L. L. Effect of 6 months use of a dentifrice and oral rinse containing sanguinaria extract and zinc chloride upon the microflora of the dental plaque and oral soft tissues. J.Periodontol. 1990;61(6):359-363. View abstract.
JOHNSON, C. C., JOHNSON, G., and POE, C. F. Toxicity of alkaloids to certain bacteria. II. Berberine, physostigmine, and sanguinarine. Acta Pharmacol Toxicol (Copenh) 1952;8(1):71-78. View abstract.
Klewansky, P. and Roth, D. Sanguinaria in the control of bleeding in periodontal patients. Compend.Contin.Educ.Dent. 1986;Suppl 7:S218-S220. View abstract.
Klewansky, P. and Vernier, D. Sanguinarine and the control of plaque in dental practice. Compend Cont Edu Dent 1984;Supp 5:S94-S97.
Kopczyk, R. A., Abrams, H., Brown, A. T., Matheny, J. L., and Kaplan, A. L. Clinical and microbiological effects of a sanguinaria-containing mouthrinse and dentifrice with and without fluoride during 6 months of use. J.Periodontol. 1991;62(10):617-622. View abstract.
Kroger, P. W., Kopczyk, R. A., Abrams, H., Kaplan, A. L., Matheny, J. K., and Japser, S. J. Effects of a sanguinarine mouthrinse after periodontal surgery. J Dent Res 1988;67:571.
Kuftinec, M. M., Mueller-Joseph, L. J., and Kopczyk, R. A. Sanguinaria toothpaste and oral rinse regimen clinical efficacy in short- and long-term trials. J.Can.Dent.Assoc. 1990;56(7 Suppl):31-33. View abstract.
Kurbad, A., Gangler, P., and Kaufmann, K. [Evaluation of the efficacy of sanguinarine using the experimental gingivitis model]. Stomatol.DDR. 1990;40(4):157-159. View abstract.
Laster, L. L. and Lobene, R. R. New perspectives on Sanguinaria clinicals: individual toothpaste and oral rinse testing. J.Can.Dent.Assoc. 1990;56(7 Suppl):19-30. View abstract.
Lobene, R. R., Soparkar, P. M., and Newman, M. B. The effects of a sanguinaria dentrifice on plaque and gingivitis. Compend.Contin.Educ.Dent. 1986;Suppl 7:S185-S188. View abstract.
Mahady, G. B., Pendland, S. L., Stoia, A., and Chadwick, L. R. In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria canadensis and Hydrastis canadensis. Phytother Res 2003;17(3):217-221. View abstract.
Mallatt, M. E., Beiswanger, B. B., Drook, C. A., Stookey, G. K., Jackson, R. D., and Bricker, S. L. Clinical effect of a sanguinaria dentifrice on plaque and gingivitis in adults. J.Periodontol. 1989;60(2):91-95. View abstract.
Mauriello, S. M. and Bader, J. D. Six-month effects of a sanguinarine dentifrice on plaque and gingivitis. J Periodontol. 1988;59(4):238-243. View abstract.
Miller, R. A., McIver, J. E., and Gunsolley, J. C. Effects of sanguinaria extract on plaque retention and gingival health. J.Clin.Orthod. 1988;22(5):304-307. View abstract.
Moran, J., Addy, M., and Newcombe, R. A clinical trial to assess the efficacy of sanguinarine-zinc mouthrinse (Veadent) compared with chlorhexidine mouthrinse (Corsodyl). J Clin Periodontol. 1988;15(10):612-616. View abstract.
Moran, J., Addy, M., and Roberts, S. A comparison of natural product, triclosan and chlorhexidine mouthrinses on 4-day plaque regrowth. J Clin Periodontol. 1992;19(8):578-582. View abstract.
Nelson, R. F., Rodasti, P. C., Tichnor, A., and Lio, Y. L. Comparative study of four over-the-counter mouthrinses claiming antiplaque and/or antigingivitis benefits. Clin Prev.Dent. 1991;13(6):30-33. View abstract.
Newton, S. M., Lau, C., Gurcha, S. S., Besra, G. S., and Wright, C. W. The evaluation of forty-three plant species for in vitro antimycobacterial activities; isolation of active constituents from Psoralea corylifolia and Sanguinaria canadensis. J.Ethnopharmacol. 2002;79(1):57-67. View abstract.
Nuckols, P. F., Koertge, T. E., Bower, S. B., and Gunsolley, J. C. Effectiveness of a Viadent mouthrinse in para- and quadriplegic patients. J Dent Res 1987;66:369.
Palcanis, K. G., Formica, J. V., Miller, R. A., Brooks, C. N., and Gunsolley, J. C. Longitudinal evaluation of sanguinaria: clinical and microbiologic studies. Compend.Contin.Educ.Dent. 1986;Suppl 7:S179-S184. View abstract.
Paolantonio, M., Di Murro, C., D'Onofrio, V., Benigni, A., and Scaramella, G. [Comparative evaluation of 2 antiplaque mouthwashes containing chlorhexidine and sanguinarine]. Minerva Stomatol. 1989;38(4):455-459. View abstract.
Parsons, L. G., Thomas, L. G., Southard, G. L., Woodall, I. R., and Jones, B. J. Effect of sanguinaria extract on established plaque and gingivitis when supragingivally delivered as a manual rinse or under pressure in an oral irrigator. J.Clin.Periodontol. 1987;14(7):381-385. View abstract.
Parsons, L. G., Thomas, L. G., Woodall, I. R., and Jones, B. J. Effect of 0.03% sanguinaria rinse on plaque and gingivitis when delivered as a manual rinse and under pressure in an oral irrigator. Compend.Contin.Educ.Dent. 1986;Suppl 7:S205-S208. View abstract.
Polson, A. M., Garrett, S., Stoller, N. H., Bandt, C. L., Hanes, P. J., Killoy, W. J., Southard, G. L., Duke, S. P., Bogle, G. C., Drisko, C. H., and Friesen, L. R. Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results. J Periodontol. 1997;68(2):119-126. View abstract.
Polson, A. M., Stoller, N. H., Hanes, P. J., Bandt, C. L., Garrett, S., and Southard, G. L. 2 multi-center trials assessing the clinical efficacy of 5% sanguinarine in a biodegradable drug delivery system. J Clin Periodontol. 1996;23(8):782-788. View abstract.
Quirynen, M., Marechal, M., and van Steenberghe, D. Comparative antiplaque activity of sanguinarine and chlorhexidine in man. J Clin Periodontol. 1990;17(4):223-227. View abstract.
Rau, I. and Bossmann, K. [Effects of dequalinium chloride and sanguinarine on the ultrastructure of early supragingival plaque]. Oralprophylaxe. 1991;13(4):133-141. View abstract.
Southard, G. L., Parsons, L. G., Thomas, L. G., Jr., Boulware, R. T., Woodall, I. R., and Jones, B. J. The relationship of sanguinaria extract concentration and zinc ion to plaque and gingivitis. J.Clin.Periodontol. 1987;14(6):315-319. View abstract.
Southard, G. L., Parsons, L. G., Thomas, L. G., Woodall, I. R., and Jones, B. J. Effect of sanguinaria extract on development of plaque and gingivitis when supragingivally delivered as a manual rinse or under pressure in an oral irrigator. J Clin Periodontol. 1987;14(7):377-380. View abstract.
Stickl, O. Die bactericide wirkung der extrakte und alkaloide des schollkrautes auf grampositive pathogene mikroorganisme. Z Hyg infektionskr 1928;108:801-867.
Tenenbaum, H., Dahan, M., and Soell, M. Effectiveness of a sanguinarine regimen after scaling and root planing. J Periodontol. 1999;70(3):307-311. View abstract.
Vichkanova, S. A. and Adgina, V. V. The antifungal properties of Sanguinarine. Antibiotiki (Moscow) 1971;16:609-612.
Vichkanova, S. A., Rubinchik, M. A., Adgina, V. V., and Fedorchenko, T. S. A study of the chemotherapeutic action of Sanguinarine. Farmakol Toksokol (Moscow) 1969;32:325-328.
Wennstrom, J. and Lindhe, J. Clinical effectiveness of a sanguinarine mouthrinse on plaque and gingivitis. Journal of Dental Research 1984;63:224.
Wennstrom, J. and Lindhe, J. Some effects of a Sanguinarine-containing mouthrinse on developing plaque and gingivitis. J Clin Periodontol. 1985;12(10):867-872. View abstract.
Wennstrom, J. and Lindhe, J. The effect of mouthrinses on parameters characterizing human periodontal disease. J Clin Periodontol. 1986;13(1):86-93. View abstract.
Becci PJ, Schwartz H, Barnes HH, Southard GL. Short-term toxicity studies of sanguinarine and of two alkaloid extracts of Sanguinaria canadensis L. J Toxicol Environ Health 1987;20:199-208. View abstract.
Cienki JJ, Zaret L. An Internet misadventure: bloodroot salve toxicity. J Altern Complement Med. 2010;16(10):1125-7. View abstract.
Harkrader RJ, Reinhart PC, Rogers JA, et al. The history, chemistry and pharmacokinetics of Sanguinaria extract. J Can Dent Assoc 1990;56:7-12. View abstract.
Hou JL, Brewer JD. Black salve and bloodroot extract in dermatologic conditions. Cutis. 2015;95(6):309-11. View abstract.
Schilling LM, Saedi N. Bloodroot paste: what dermatologists and patients need to know. Dermatol Surg 2016;42(10):1223-4. View abstract.
Schlichte MJ, Downing CP, Ramirez-Fort M, Gordon R, Tyring S. Bloodroot associated eschar. Dermatol Online J 2014;20(7). View abstract.
Seifen E, Adams RJ, Riemer RK. Sanguinarine: a positive inotropic alkaloid which inhibits cardiac Na+,K+-ATPase. Eur J Pharmacol 1979;60:373-7. View abstract.
Select a condition to view a list of vitamins
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2024 by Therapeutic Research Center, LLC. All Rights Reserved.